Korean J Gastroenterol.  2016 Sep;68(3):169-171. 10.4166/kjg.2016.68.3.169.

Antitumor Effects of Somatostatin Analogs in Gastroenteropancreatic Neuroendocrine Tumors

• Cho JH

• KMID: 2358722
• DOI: http://doi.org/10.4166/kjg.2016.68.3.169

Abstract

No abstract available.

MeSH Terms

Neuroendocrine Tumors*
Somatostatin*
Somatostatin

Reference

References

1. Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014; 371:224–233.

2. Cho JH, Song SY, Lee TH, et al. Gastroenteropancreatic neuroendocrine tumor. 1st ed.Seoul: Korean Society of Gastrointestinal Cancer;2012.

3. Sun JM, Jung HC. Gastrointestinal carcinoid tumor. Korean J Gastroenterol. 2004; 44:59–65.

4. Neuroendocrine Tumors (Version 2.2016). [Internet]. Fort Washington (PA): National Comprehensive Cancer Network (NCCN); [updated 2016 May 25;cited 2016 Jun 1]. Available from:. http://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf.

5. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364:514–523.

6. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364:501–513.

7. Aparicio T, Ducreux M, Baudin E, et al. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer. 2001; 37:1014–1019.

8. Saltz L, Trochanowski B, Buckley M, et al. Octreotide as an anti-neoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer. 1993; 72:244–248.

9. Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut. 1996; 38:430–438.

10. Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009; 27:4656–4663.